Navigation Links
Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
Date:1/4/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/-- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its Chairman and CEO James A. Joyce will be the lead-off presenter at the Biotech Showcase™ 2012. Mr. Joyce's presentation will begin at 9:00 am Pacific Time on January 9th, 2012.  A live webcast of the presentation will be available at:

http://www.media-server.com/m/p/dfvbu2du

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

About Biotech Showcase™

Biotech Showcase™ is a forum devoted to providing biotechnology companies, investors and pharmaceutical executives with an opportunity to meet in one place during the course of one of the world's largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.

Now in its fourth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule one-to-one partnering meetings and networking. The attendees to the showcase include private and public equity investors, analysts, bankers, biopharmaceutical industry executives and other industry professionals.  The event is being held at the Parc 55 Wyndham San Francisco – Union Square. 

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com

 

 

 

 


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
2. Aethlon Medical Releases Shareholder Letter
3. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
4. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
5. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
6. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
7. Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
8. Aethlon Medical Releases Shareholder Letter
9. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
10. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
11. Aethlon Medical Clarifies News Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 A ReportsnReports.com report says, over the ... as the global sales of Adcetris and Kadcyla have been witnessing ... drug conjugates market is driven by large number of ADC drugs ... window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company Profiles, ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA (OSE: ... complete 2016 Annual Accounts with notes. The report is attached ... the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, please ... Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media enquiries: ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... ... Swissray is pleased to announce the release of the ELITE DXA, a new bone ... scan window, which is more than double that of existing bone densitometers. Historically, subjects ... an accurate total body bone density or body composition study. The ELITE DXA ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... new clinic which can be found at 9618 Huebner Road. The clinic is the ... PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, Scanlan ... to announce Westchester resident Lauren C. Enea has joined the firm as an associate ... concentrate her practice in elder law, Medicaid planning and applications, and Wills, Trusts and ...
Breaking Medicine News(10 mins):